112 related articles for article (PubMed ID: 17908972)
1. Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions.
Salani R; Davidson B; Fiegl M; Marth C; Müller-Holzner E; Gastl G; Huang HY; Hsiao JC; Lin HS; Wang TL; Lin BL; Shih IeM
Clin Cancer Res; 2007 Oct; 13(19):5805-9. PubMed ID: 17908972
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon.
Lin L; Prescott MS; Zhu Z; Singh P; Chun SY; Kuick RD; Hanash SM; Orringer MB; Glover TW; Beer DG
Cancer Res; 2000 Dec; 60(24):7021-7. PubMed ID: 11156406
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
Passebosc-Faure K; Li G; Lambert C; Cottier M; Gentil-Perret A; Fournel P; Pérol M; Genin C
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6862-7. PubMed ID: 16203775
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions.
Economidou F; Tzortzaki EG; Schiza S; Antoniou KM; Neofytou E; Zervou M; Lambiri I; Siafakas NM
Oncol Rep; 2007 Dec; 18(6):1507-12. PubMed ID: 17982637
[TBL] [Abstract][Full Text] [Related]
5. Cyclin E mRNA overexpression in epithelial ovarian cancers: inverse correlation with p53 protein accumulation.
Sawasaki T; Shigemasa K; Shiroyama Y; Kusuda T; Fujii T; Parmley TH; O'Brien TJ; Ohama K
J Soc Gynecol Investig; 2001; 8(3):179-85. PubMed ID: 11390254
[TBL] [Abstract][Full Text] [Related]
6. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma.
Peng SY; Chou SP; Hsu HC
J Hepatol; 1998 Aug; 29(2):281-9. PubMed ID: 9722210
[TBL] [Abstract][Full Text] [Related]
7. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling.
Fernandez-Ranvier GG; Weng J; Yeh RF; Khanafshar E; Suh I; Barker C; Duh QY; Clark OH; Kebebew E
Arch Surg; 2008 Sep; 143(9):841-6; discussion 846. PubMed ID: 18794420
[TBL] [Abstract][Full Text] [Related]
8. Amplicon profiles in ovarian serous carcinomas.
Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
[TBL] [Abstract][Full Text] [Related]
9. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
Etemadmoghadam D; deFazio A; Beroukhim R; Mermel C; George J; Getz G; Tothill R; Okamoto A; Raeder MB; Harnett P; Lade S; Akslen LA; Tinker AV; Locandro B; Alsop K; Chiew YE; Traficante N; Fereday S; Johnson D; Fox S; Sellers W; Urashima M; Salvesen HB; Meyerson M; Bowtell D;
Clin Cancer Res; 2009 Feb; 15(4):1417-27. PubMed ID: 19193619
[TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA concentration and integrity as a screening tool for cancer.
Zaher ER; Anwar MM; Kohail HM; El-Zoghby SM; Abo-El-Eneen MS
Indian J Cancer; 2013; 50(3):175-83. PubMed ID: 24061455
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
[TBL] [Abstract][Full Text] [Related]
12. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas.
Wu R; Lin L; Beer DG; Ellenson LH; Lamb BJ; Rouillard JM; Kuick R; Hanash S; Schwartz DR; Fearon ER; Cho KR
Am J Pathol; 2003 May; 162(5):1603-10. PubMed ID: 12707044
[TBL] [Abstract][Full Text] [Related]
13. Increased plasma DNA integrity in cancer patients.
Wang BG; Huang HY; Chen YC; Bristow RE; Kassauei K; Cheng CC; Roden R; Sokoll LJ; Chan DW; Shih IeM
Cancer Res; 2003 Jul; 63(14):3966-8. PubMed ID: 12873992
[TBL] [Abstract][Full Text] [Related]
14. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
15. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors.
Schmidt BA; Rose A; Steinhoff C; Strohmeyer T; Hartmann M; Ackermann R
Cancer Res; 2001 May; 61(10):4214-21. PubMed ID: 11358847
[TBL] [Abstract][Full Text] [Related]
17. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary.
Tsuda H; Bandera CA; Birrer MJ; Hashiguchi Y; Berkowitz RS; Mok SC
Oncology; 2004; 67(3-4):291-9. PubMed ID: 15557791
[TBL] [Abstract][Full Text] [Related]
18. Different expression of FoxM1 in human benign and malignant pleural effusion.
Tang Z; Li H; Zhu H; Bai C
Med Oncol; 2015 Jan; 32(1):312. PubMed ID: 25491139
[TBL] [Abstract][Full Text] [Related]
19. Improved DOP-PCR-based representational whole-genome amplification using quantitative real-time PCR.
Fehér LZ; Balázs M; Kelemen JZ; Zvara A; Németh I; Varga-Orvos Z; Puskás LG
Diagn Mol Pathol; 2006 Mar; 15(1):43-8. PubMed ID: 16531768
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
